A growing body of evidence suggests that what happens in the gut is tied to what happens in the brain. A Yale study led by Erin Longbrake, MD, PhD, reports meaningful differences between the gut bacteria of people newly diagnosed with multiple sclerosis and those of healthy individuals. The researchers also tracked how these microbes and their interactions with the immune system shift after B-cell depletion therapy.<\/p>\n\n\n\n
Your intestines are lined with immune cells that tag certain bacteria so the body can keep them under control. The Yale team found that in people with new-onset multiple sclerosis the immune system tags fewer gut bacteria. That suggests the body may be misreading some microbes at the exact time MS is beginning. If doctors can read those microbial patterns, they could one day help predict risk, diagnose earlier, or monitor how well treatment is working.<\/p>\n\n\n\n
The study appears in Neurology Neuroimmunology & Neuroinflammation<\/em> and was conducted by a Yale University team that includes Erin E. Longbrake, Vinod K. Gupta, Guneet S. Janda, Heather K. Pump, Nikhil Lele, Isabella Cruz, Inessa Cohen, William E. Ruff, David A. Hafler, and Jaeyun Sung. The investigators recruited 43 people with newly diagnosed, untreated multiple sclerosis and 42 matched healthy controls. All participants provided stool samples, and a subset of 19 patients with MS provided a second sample six months after starting anti-CD20 B-cell depletion therapy such as ocrelizumab or rituximab.<\/p>\n\n\n\n The team focused on immunoglobulin A, or IgA, an antibody secreted into the gut that binds to specific microbes. Compared with healthy individuals, people with untreated MS had a smaller proportion of IgA-coated bacteria. As Longbrake explains, \u201cThe fact that fewer bacteria were coated with IgA in patients with MS suggests that there is perhaps a fundamental disconnect going on with the host-microbe interactions.\u201d The researchers did not find evidence that this drop was because MS patients lacked the usual IgA-targeted strains. Instead, it looked like a change in how the immune system was recognizing and coating microbes.<\/p>\n\n\n\n The study identified specific bacteria that shifted in abundance or prevalence. A beneficial butyrate producer, Faecalibacterium prausnitzii<\/em>, was less abundant in MS. This matches earlier reports. A pectin-degrading species, Monoglobus pectinilyticus<\/em>, was more abundant in untreated MS and more prevalent across samples. There were also shifts among short-chain fatty acid producers within the IgA-coated and uncoated fractions, including Coprococcus comes<\/em> and Ruminococcus<\/em> variants. The total bacterial community showed significant differences in both alpha and beta diversity between MS and controls, even though the sorted IgA-positive and IgA-negative fractions did not.<\/p>\n\n\n\n Nineteen patients provided follow-up samples six months after starting B-cell depletion therapy. Their overall proportion of IgA-coated bacteria did not rise, yet the composition and immune tagging of several organisms shifted in ways that moved closer to healthy patterns. The authors note that for some strains, particularly Akkermansia muciniphila<\/em>, IgA-coating after therapy \u201cbecame more aligned with controls.\u201d Longbrake adds, \u201cThis gives us some clues into the mechanisms underlying how this type of drug works to treat MS.\u201d In other words, therapy seems to alter the strain-specific conversation between microbes and the immune system even if it does not simply increase total IgA tagging.<\/p>\n\n\n\n The paper points to several lines of evidence that connect gut ecology to autoimmune activity in the central nervous system. Prior studies show that certain T cells inside MS lesions can recognize a human autoantigen with a conserved bacterial homolog, which suggests cross-reactivity. Epsilon toxin-producing Clostridium perfringens<\/em> has been found more often in MS and can boost autoimmune brain inflammation in models. Fecal microbial transfer from people with MS has induced more spontaneous brain autoimmunity in a transgenic mouse model than transfers from unaffected twins. Taken together, these findings outline a pathway where changes in gut microbes and the immune response to them may help trigger or amplify disease activity in the brain.<\/p>\n\n\n\n Longbrake underscores how the microbiome sits at the crossroads of lifestyle and immunity. \u201cThe microbiome interfaces with the environment as well as the immune system,\u201d she says. That means environmental risk factors such as diet and smoking \u201ccould predispose people to MS because they change the bugs that are in the gut.\u201d The team also highlights that after B-cell depletion some organisms \u201cdisplayed immune coating patterns more similar to those of controls,\u201d a clue that the therapy may help re-establish healthier immune-microbe relationships rather than simply increasing antibody levels in the gut.<\/p>\n\n\n\n Participants were carefully screened to avoid recent antibiotics, irritable bowel syndrome, or small intestinal bacterial overgrowth. Samples were collected at home, frozen, and shipped to Yale between 2018 and 2021. The laboratory separated total bacteria into IgA-coated and uncoated fractions, quantified immunoglobulin coatings by flow cytometry, and used long-read sequencing to achieve strain-level resolution. Statistical models adjusted for age, sex, body mass index, and steroid use. In total, 43 untreated MS patients and 42 controls were analyzed at baseline, with 19 MS patients sampled again after six months on anti-CD20 therapy.<\/p>\n\n\n\n The authors are careful about limits. They note that the study is observational and cannot prove which strains are drivers rather than passengers. Differences from prior reports may reflect the enhanced resolution of long-read sequencing, geographic factors, or methodological variation. They also chose to present uncorrected significance for many tests to avoid missing true signals in this exploratory, strain-level analysis. Still, the pattern is consistent. New-onset MS shows a reduction in IgA-coated microbes, shifts in key strains, and fewer taxa with strong IgA-coating signatures. After B-cell depletion, some of those strain-specific immune tags move toward healthy patterns.<\/p>\n\n\n\n The team sees several priorities. Larger, multi-site cohorts are needed to confirm strain-level signals and to map microbial networks rather than single organisms. Mechanistic studies should test whether restoring short-chain fatty acid producers, supporting the gut barrier, or rebalancing IgA-microbe interactions can change clinical outcomes. As the authors put it, these shifts \u201csuggest the potential for leveraging these changes as biomarkers or therapeutic targets.\u201d MS has long been seen as a disease of the central nervous system. This research suggests it is also a disease of a conversation, where the immune system in the gut learns to read microbes. Teaching that immune system to read better may change the course of the story<\/p>\n","protected":false},"excerpt":{"rendered":" A growing body of evidence suggests that what happens in the gut is tied to what happens in the brain. A Yale study led by Erin Longbrake, MD, PhD, reports meaningful differences between the gut bacteria of people newly diagnosed with multiple sclerosis and those of healthy individuals. The researchers also tracked how these microbes and their interactions with the immune system shift after B-cell depletion therapy. Your intestines are lined with immune cells that tag certain bacteria so the […]<\/p>\n","protected":false},"author":2,"featured_media":7100,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[15,6],"tags":[],"class_list":["post-7099","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-cancer-research","category-conditions"],"_links":{"self":[{"href":"https:\/\/healthnews.zone\/index.php?rest_route=\/wp\/v2\/posts\/7099","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/healthnews.zone\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/healthnews.zone\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/healthnews.zone\/index.php?rest_route=\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/healthnews.zone\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=7099"}],"version-history":[{"count":1,"href":"https:\/\/healthnews.zone\/index.php?rest_route=\/wp\/v2\/posts\/7099\/revisions"}],"predecessor-version":[{"id":7101,"href":"https:\/\/healthnews.zone\/index.php?rest_route=\/wp\/v2\/posts\/7099\/revisions\/7101"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/healthnews.zone\/index.php?rest_route=\/wp\/v2\/media\/7100"}],"wp:attachment":[{"href":"https:\/\/healthnews.zone\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=7099"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/healthnews.zone\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=7099"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/healthnews.zone\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=7099"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}The central finding about IgA<\/h4>\n\n\n\n
What changed in the gut community<\/h4>\n\n\n\n
What treatment reveals about mechanism<\/h4>\n\n\n\n
Potential uses of this linkage<\/h4>\n\n\n\n
\n
Study design in more detail<\/h4>\n\n\n\n